RenovoRx, Inc. Cash Flow Statement
RNXT|2 years of annual SEC 10-K data (FY2024-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$9M
FY2025
Free Cash Flow
-$9M
FY2025
Capital Expenditures
$12,000
Cash used for long-term assets
Dividends Paid
N/A
FY2025
RenovoRx, Inc. used $9M in operating cash flow and negative free cash flow of $9M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 1/9 criteria passed
- Currently unprofitable: Net income is negative
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Net Income | -$8.8M | -$10.2M |
| Depreciation & Amortization | $0 | - |
| Operating Cash Flow | -$9.1M | -$10.3M |
| Capital Expenditures | $12.0K | $12.0K |
| Free Cash Flow | -$9.1M | -$10.3M |
| FCF Margin | -21248.8% | -23883.7% |